A Randomised, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP)
A platform trial for severely ill patients with COVID-19. It aims to generate evidence that can be applied during the pandemic to reduce mortality, reduce ICU use, and reduce morbidity in severely ill patients with COVID-19 infection.
| Imperial PI | Professor Anthony Gordon (UK Lead) |
| Trial Sponsor | University Medical Center, Utrecht |
| Study type | Interventional |
| Study status | In recruitment |
Find out more about this study here.
Information for study delivery staff at sites Protocol